首页> 外文期刊>Antimicrobial agents and chemotherapy. >Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.
【24h】

Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.

机译:喜树碱和亚硝胺衍生物对真菌和癌细胞的体外活性比较。

获取原文
获取原文并翻译 | 示例
           

摘要

The activities of a series of camptothecin and nitidine derivatives that might interact with topoisomerase I were compared against yeast and cancer cell lines. Our findings reveal that structural modifications to camptothecin derivatives have profound effects on the topoisomerase I-drug poison complex in cells. Although the water-soluble anticancer agents topotecan and irinotecan are less active than the original structure, camptothecin, other derivatives or analogs with substitutions that increase compound solubility have also increased antifungal activities. In fact, a water-soluble prodrug appears to penetrate into the cell and release its active form; the resulting effect in complex with Cryptococcus neoformans topoisomerase I is a fungicidal response and also potent antitumor activity. Some of the compounds that are not toxic to wild-type yeast cells are extremely toxic to the yeast cells when the C. neoformans topoisomerase I target is overexpressed. With the known antifungal mechanism of a camptothecin-topoisomerase I complex as a cellular poison, these findings indicate that drug entry may be extremely important for antifungal activity. Nitidine chloride exhibits antifungal activity against yeast cells through a mechanism(s) other than topoisomerase I and appears to be less active than camptothecin analogs against tumor cells. Finally, some camptothecin analogs exhibit synergistic antifungal activity against yeast cells in combination with amphotericin B in vitro. Our results suggest that camptothecin and/or nitidine derivatives can exhibit potent antifungal activity and that the activities of camptothecin derivatives with existing antifungal drugs may be synergistic against pathogenic fungi. These new compounds, which exhibit potent antitumor activities, will likely require further structural changes to find more selective activity against fungal versus mammalian cells to hold promise as a new class of antifungal agents.
机译:将一系列可能与拓扑异构酶I相互作用的喜树碱和亚硝胺衍生物的活性与酵母和癌细胞系进行了比较。我们的发现表明,喜树碱衍生物的结构修饰对细胞中的拓扑异构酶I-药物毒性复合物具有深远的影响。尽管水溶性抗癌药托泊替康和伊立替康的活性不及原始结构,喜树碱,其他衍生物或类似物(其替代物会增加化合物的溶解度)也增加了抗真菌活性。实际上,水溶性前药似乎渗透到细胞中并释放其活性形式。与新型隐球菌拓扑异构酶I配合使用时所产生的作用是杀真菌反应,也是有效的抗肿瘤活性。当新形成梭状芽胞杆菌拓扑异构酶I靶标过表达时,一些对野生型酵母细胞无毒的化合物对酵母细胞具有极高的毒性。利用喜树碱-拓扑异构酶I复合物作为细胞毒物的已知抗真菌机制,这些发现表明,药物进入对于抗真菌活性可能极为重要。氯化亚硝胺通过拓扑异构酶I以外的其他机制对酵母细胞表现出抗真菌活性,并且似乎比喜树碱类似物对肿瘤细胞的活性低。最后,一些喜树碱类似物在体外与两性霉素B结合表现出针对酵母细胞的协同抗真菌活性。我们的结果表明,喜树碱和/或亚硝胺衍生物可表现出强大的抗真菌活性,喜树碱衍生物与现有抗真菌药物的活性可能对病原真菌具有协同作用。这些具有强大的抗肿瘤活性的新化合物可能需要进一步的结构变化,以发现对真菌细胞和哺乳动物细胞的更多选择性活性,从而有望作为一类新型的抗真菌剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号